Effectiveness of Maternal Vaccination with mRNA COVID-19 Vaccine During Pregnancy Against COVID-19-Associated Hospitalization in Infants Aged <6 Months - 17 States, July 2021-January 2022
- PMID: 35176002
- PMCID: PMC8853480
- DOI: 10.15585/mmwr.mm7107e3
Effectiveness of Maternal Vaccination with mRNA COVID-19 Vaccine During Pregnancy Against COVID-19-Associated Hospitalization in Infants Aged <6 Months - 17 States, July 2021-January 2022
Abstract
COVID-19 vaccination is recommended for persons who are pregnant, breastfeeding, trying to get pregnant now, or who might become pregnant in the future, to protect them from COVID-19.§ Infants are at risk for life-threatening complications from COVID-19, including acute respiratory failure (1). Evidence from other vaccine-preventable diseases suggests that maternal immunization can provide protection to infants, especially during the high-risk first 6 months of life, through passive transplacental antibody transfer (2). Recent studies of COVID-19 vaccination during pregnancy suggest the possibility of transplacental transfer of SARS-CoV-2-specific antibodies that might provide protection to infants (3-5); however, no epidemiologic evidence currently exists for the protective benefits of maternal immunization during pregnancy against COVID-19 in infants. The Overcoming COVID-19 network conducted a test-negative, case-control study at 20 pediatric hospitals in 17 states during July 1, 2021-January 17, 2022, to assess effectiveness of maternal completion of a 2-dose primary mRNA COVID-19 vaccination series during pregnancy against COVID-19 hospitalization in infants. Among 379 hospitalized infants aged <6 months (176 with COVID-19 [case-infants] and 203 without COVID-19 [control-infants]), the median age was 2 months, 21% had at least one underlying medical condition, and 22% of case- and control-infants were born premature (<37 weeks gestation). Effectiveness of maternal vaccination during pregnancy against COVID-19 hospitalization in infants aged <6 months was 61% (95% CI = 31%-78%). Completion of a 2-dose mRNA COVID-19 vaccination series during pregnancy might help prevent COVID-19 hospitalization among infants aged <6 months.
Conflict of interest statement
All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Adrienne G. Randolph reports institutional support from the National Institute of Allergy and Infectious Diseases and National Institutes of Health (NIH) and being the UpToDate Pediatric Critical Care Section Editor. Matt S. Zinter reports institutional support from the National Heart, Lung, and Blood Institute (NHLBI), NIH and the American Thoracic Society. Laura Smallcomb reports support from the Medical University of South Carolina for conference attendance. Jennifer E. Schuster reports institutional support from Merck. Ryan A. Nofziger reports institutional support from NIH. Emily R. Levy reports institutional support from NIH. Michele Kong reports institutional support from NIH. Satoshi Kamidani reports institutional support from NIH and Pfizer. Janet R. Hume reports institutional support from the National Institute for Child Health and Development, NIH, and serving on a data safety monitoring board for an institutional study of magnesium for analgesia in complex medical patients. Charlotte V. Hobbs reports consultant fees from BioFire (bioMérieux). Natalie Z. Cvijanovich reports institutional support from NIH. Bria M. Coates reports institutional support from NHLBI, NIH, the American Lung Association, and the American Thoracic Society. Kathleen Chiotos reports institutional support from the Agency for Healthcare Research and Quality and serving as the Society for Healthcare Epidemiology of America Research Network Chair. Samina S. Bhumbra reports receipt of an NIH, National Institute for Allergy and Infectious Diseases training grant. Pia S. Pannaraj reports institutional support from AstraZeneca and Pfizer, consulting fees from Sanofi-Pasteur and Seqirus, payment from law firms for expert testimony, serving in the Division of Microbiology and Infectious Diseases, and unpaid service on the California Immunization Coalition. Mary A. Staat reports institutional support from NIH and receipt of lecture fees from the American Academy of Pediatrics for PREP ID Course. Natasha B. Halasa reports grant support from Sanofi and Quidel and honoraria from Genentech. No other potential conflicts of interest were disclosed.
Similar articles
-
Maternal Vaccination and Risk of Hospitalization for Covid-19 among Infants.N Engl J Med. 2022 Jul 14;387(2):109-119. doi: 10.1056/NEJMoa2204399. Epub 2022 Jun 22. N Engl J Med. 2022. PMID: 35731908 Free PMC article.
-
Effectiveness of Maternal mRNA COVID-19 Vaccination During Pregnancy Against COVID-19-Associated Hospitalizations in Infants Aged <6 Months During SARS-CoV-2 Omicron Predominance - 20 States, March 9, 2022-May 31, 2023.MMWR Morb Mortal Wkly Rep. 2023 Sep 29;72(39):1057-1064. doi: 10.15585/mmwr.mm7239a3. MMWR Morb Mortal Wkly Rep. 2023. PMID: 37874864 Free PMC article.
-
Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.MMWR Morb Mortal Wkly Rep. 2022 Feb 18;71(7):255-263. doi: 10.15585/mmwr.mm7107e2. MMWR Morb Mortal Wkly Rep. 2022. PMID: 35176007 Free PMC article.
-
Systematic Literature Review of Maternal Antibodies in Human Milk Following Vaccination During Pregnancy or Lactation: Tetanus, Pertussis, Influenza and COVID-19.Pediatr Infect Dis J. 2025 Feb 1;44(2S):S38-S42. doi: 10.1097/INF.0000000000004634. Epub 2025 Feb 14. Pediatr Infect Dis J. 2025. PMID: 39951072
-
Role of maternal COVID-19 vaccination in providing immunological protection to the newborn.Pharmacotherapy. 2022 Jan;42(1):58-70. doi: 10.1002/phar.2649. Epub 2021 Dec 15. Pharmacotherapy. 2022. PMID: 34816467 Review.
Cited by
-
COVID-19 Vaccination and Reproductive Health: a Comprehensive Review for Healthcare Providers.Reprod Sci. 2024 May;31(5):1215-1226. doi: 10.1007/s43032-023-01428-0. Epub 2023 Dec 27. Reprod Sci. 2024. PMID: 38151655 Review.
-
Impact of prenatal COVID-19 vaccination on delivery and neonatal outcomes: Results from a New York City cohort.Vaccine. 2023 Jan 16;41(3):649-656. doi: 10.1016/j.vaccine.2022.09.095. Epub 2022 Dec 14. Vaccine. 2023. PMID: 36526507 Free PMC article.
-
Maternal transfer of IgA and IgG SARS-CoV-2 specific antibodies transplacentally and via breast milk feeding.PLoS One. 2023 Apr 6;18(4):e0284020. doi: 10.1371/journal.pone.0284020. eCollection 2023. PLoS One. 2023. PMID: 37023025 Free PMC article.
-
Lack of clear national policy guidance on COVID-19 vaccines influences behaviors in pregnant and lactating women in Kenya.Hum Vaccin Immunother. 2022 Nov 30;18(6):2127561. doi: 10.1080/21645515.2022.2127561. Epub 2022 Oct 31. Hum Vaccin Immunother. 2022. PMID: 36315852 Free PMC article.
-
Pregnant women with mild COVID-19 followed in community setting by telemedicine, and factors associated with unfavorable outcome.PLoS One. 2023 Aug 3;18(8):e0288845. doi: 10.1371/journal.pone.0288845. eCollection 2023. PLoS One. 2023. PMID: 37535653 Free PMC article.
References
-
- Yang YJ, Murphy EA, Singh S, et al. Association of gestational age at coronavirus disease 2019 (COVID-19) vaccination, history of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, and a vaccine booster dose with maternal and umbilical cord antibody levels at delivery. Obstet Gynecol 2021. Epub December 28, 2021. 10.1097/AOG.0000000000004693 - DOI - PubMed